We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

391 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 41

65% more call options, than puts

Call options by funds: $93.9M | Put options by funds: $56.8M

33% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 103

18% more capital invested

Capital invested by funds: $8.09B → $9.56B (+$1.48B)

18% more funds holding

Funds holding: 332 → 391 (+59)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

1.37% less ownership

Funds ownership: 98.02% → 96.65% (-1.4%)

Holders
391
Holders Change
+59
Holders Change %
+17.77%
% of All Funds
7.7%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
109
Increased
137
Reduced
103
Closed
41
Calls
$93.9M
Puts
$56.8M
Net Calls
+$37.1M
Net Calls Change
+$33.9M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$77M
2
BlackRock
BlackRock
New York
+$68.6M
3
State Street
State Street
Massachusetts
+$65.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$58.7M
5
Ameriprise
Ameriprise
Minnesota
+$34M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$138M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$118M
3
HM
HealthCor Management
New York
-$71.9M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$68.6M
5
O
OrbiMed
New York
-$66.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
WorldQuant Millennium Advisors
251
WorldQuant Millennium Advisors
New York
$592K +$577K +5,510 New
Creative Planning
252
Creative Planning
Kansas
$591K +$22K +210 +4%
SMDAM
253
Sumitomo Mitsui DS Asset Management
Japan
$580K +$565K +5,396 New
GCA
254
Gideon Capital Advisors
New York
$562K +$548K +5,230 New
KBC Group
255
KBC Group
Belgium
$551K +$537K +5,127 New
QT
256
Quantamental Technologies
New York
$542K +$189K +1,808 +56%
PRC
257
Pearl River Capital
Michigan
$542K +$528K +5,045 New
SSWM
258
Sheets Smith Wealth Management
North Carolina
$536K +$526K +5,028 New
HighTower Advisors
259
HighTower Advisors
Illinois
$532K +$31K +296 +6%
SCM
260
Stevens Capital Management
Pennsylvania
$504K +$69K +659 +16%
IA
261
IFG Advisory
Georgia
$495K +$482K +4,607 New
Marshall Wace
262
Marshall Wace
United Kingdom
$473K -$6.51M -62,171 -93%
MC
263
Machina Capital
France
$441K +$90.6K +865 +27%
CANY
264
Caxton Associates (New York)
New York
$437K +$425K +4,061 New
Comerica Bank
265
Comerica Bank
Texas
$434K +$36.1K +345 +9%
B
266
Bailard
California
$419K -$105K -1,000 -20%
US Bancorp
267
US Bancorp
Minnesota
$410K +$71.7K +685 +22%
NICM
268
Neo Ivy Capital Management
New York
$381K +$371K +3,543 New
CIBC Asset Management
269
CIBC Asset Management
Ontario, Canada
$363K +$20.3K +194 +6%
M&T Bank
270
M&T Bank
New York
$355K -$17.6K -168 -5%
AGM
271
Alpine Global Management
New York
$348K +$339K +3,236 New
TCWM
272
Total Clarity Wealth Management
Illinois
$340K +$331K +3,160 New
JGGDR
273
JGP Global Gestao de Recursos
Brazil
$337K +$3.87K +37 +1%
9WM
274
9258 Wealth Management
Ohio
$337K +$328K +3,132 New
RFC
275
Regions Financial Corp
Alabama
$333K +$6.28K +60 +2%
9 10
11
12 13

NBIX Hedge Fund Activity: Q4 2019 in Review

391 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2019, worth a combined $9.56B — up 18% from $8.09B a quarter earlier.

Buyers outnumbered sellers: 109 funds opened new NBIX positions and 41 closed out — a net gain of 68 holders — while 137 added to existing stakes and 103 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $77M. The largest seller was Fidelity Investments, cutting an estimated $138M.

  • 391 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2019, up from 332 in Q3 2019.
  • Funds reported $9.56B of Neurocrine Biosciences stock for Q4 2019, up 18% quarter-over-quarter.
  • 109 funds opened new Neurocrine Biosciences positions in Q4 2019 and 41 closed out, a net change of +68 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $77M added.
  • The largest Neurocrine Biosciences seller in Q4 2019 was Fidelity Investments, an estimated $138M sold.

Based on aggregated 13F filings for Q4 2019.